ArticleJournal of anesthesia, analgesia and critical care2026
Safety and tolerability study of clonidine for sedation in mechanically ventilated adult patients.
Article in Journal of anesthesia, analgesia and critical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02466373 (Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClonidine is used as an adjunct sedative in mechanically ventilated ICU patients, but prospective data on the safety and tolerability of higher intravenous doses remain limited.
methodsThis secondary analysis used data from a prospective pharmacokinetic study in 32 critically ill adults. Patients were consecutively enrolled into four dose groups (0, 600, 1200 or 1800 μg/day, 8 per group) and received continuous intravenous clonidine added to standard sedation for up to seven days. Half of the patients in the clonidine groups underwent a four-hour loading phase during which the infusion rate was tripled. Serious adverse events (SAEs), a predefined set of adverse events (AEs), and outcome parameters were recorded. The relatedness of SAEs to clonidine was assessed using the WHO-UMC causality classification system. Patients were monitored for 48 h after clonidine discontinuation.
resultsTen SAEs were reported (3, 3, 3 and 1 in the 0, 600, 1200 and 1800 μg/day dose groups, respectively; Bayes factor (BF) 0.23). Seven SAEs were considered unrelated to clonidine, while three were judged possibly related. No SAEs occurred during the loading phase. No dose-dependent relationship was observed between clonidine dose and bradycardia or hypotension (BF 0.39 and 0.40, respectively). Pleural effusions were more frequent in the control group than in the clonidine groups (BF 12.9). Days on sedation, duration of mechanical ventilation, days in ICU and hospital mortality did not differ between groups. No clinically meaningful tachycardia or hypertension suggestive of clonidine withdrawal was observed.
conclusionClonidine was well tolerated within the studied dose range when used as an adjunct to standard sedation in our cohort of non-bradycardic, mechanically ventilated, critically ill adults. No clear dose-dependent increase in predefined adverse events was observed within the studied dose range. These findings provide support for further prospective evaluation of clonidine at doses up to 1800 µg/day in future efficacy studies.
trial registrationClinicalTrials.gov NCT02466373.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.